Isoxepac

Cat. No.: HY-W050088 CAS No.: 55453-87-7 Molecular Formula: $C_{16}H_{12}O_{4}$ Molecular Weight: 268.26 Others Target: Pathway: Others

Storage: Powder -20°C

2 years

3 years

-80°C In solvent 6 months

> -20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (372.77 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.7277 mL	18.6386 mL	37.2773 mL
	5 mM	0.7455 mL	3.7277 mL	7.4555 mL
	10 mM	0.3728 mL	1.8639 mL	3.7277 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Isoxepac (HP 549) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory, analgesic and antipyretic activity. Isoxepac has been studied in rat, rabbit, dog, rhesus monkey, etc^{[1][2][3]}.

REFERENCES

[1]. L S Gerlis, et al. Isoxepac in rheumatoid arthritis: a double-blind comparison with aspirin. Rheumatol Rehabil. 1981 Feb 1;20(1):50-3.

[2]. W J Honig, et al. Analgesic effect of isoxepac on postmeniscectomy pain: a controlled trial. J Clin Pharmacol. Feb-Mar 1982;22(2-3):82-8. [3]. H P Illing, et al. Species differences in the disposition and metabolism of 6,11-dihydro-11-oxodibenz[be]oxepin-2-acetic acid (isoxepac) in rat, rabbit, dog, rhesus monkey, and man. Drug Metab Dispos. Sep-Oct 1978;6(5):510-7. Caution: Product has not been fully validated for medical applications. For research use only. Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com